Cwm LLC boosted its stake in shares of Bruker Co. (NASDAQ:BRKR) by 85.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 257,040 shares of the medical research company’s stock after buying an additional 118,469 shares during the period. Cwm LLC owned approximately 0.16% of Bruker worth $8,598,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Bruker during the 2nd quarter valued at approximately $101,000. Sun Life Financial INC purchased a new stake in Bruker during the 2nd quarter valued at $163,000. First Hawaiian Bank purchased a new stake in Bruker during the 3rd quarter valued at $248,000. Strs Ohio purchased a new stake in Bruker during the 2nd quarter valued at $327,000. Finally, State of Alaska Department of Revenue boosted its stake in Bruker by 35.6% during the 2nd quarter. State of Alaska Department of Revenue now owns 11,510 shares of the medical research company’s stock valued at $334,000 after purchasing an additional 3,020 shares during the last quarter. 64.83% of the stock is owned by institutional investors.
Several analysts have commented on BRKR shares. Morgan Stanley cut their target price on Bruker from $31.00 to $29.00 and set an “equal weight” rating on the stock in a research note on Friday, July 13th. Zacks Investment Research downgraded Bruker from a “hold” rating to a “sell” rating in a research note on Tuesday, July 24th. BidaskClub upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Friday, August 24th. ValuEngine downgraded Bruker from a “buy” rating to a “hold” rating in a research note on Friday, September 21st. Finally, UBS Group started coverage on Bruker in a research note on Tuesday, October 9th. They set a “sell” rating and a $30.00 target price on the stock. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $33.90.
Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, August 2nd. The medical research company reported $0.25 EPS for the quarter, meeting the consensus estimate of $0.25. Bruker had a return on equity of 27.03% and a net margin of 4.99%. The business had revenue of $443.70 million for the quarter, compared to the consensus estimate of $436.10 million. During the same period last year, the business posted $0.23 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. On average, equities research analysts expect that Bruker Co. will post 1.38 earnings per share for the current year.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Further Reading: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.